Maravai Lifesciences Holdings stock kpis
Want to see MRVI full AI Analyst Report?
Revenue by Segment
In Q3 2026, Maravai Lifesciences Holdings reported revenue by segment of $28.35M (Nucleic Acid Production) and $17.50M (Biologics Safety Testing).
Analyzes revenue contributions from various business segments, indicating which areas are leading growth and where strategic focus might be needed.
Nucleic Acid Production (TriLink) has normalized well below the COVID peak but is showing renewed 2026 momentum as the business shifts to higher‑margin GMP and discovery mRNA sales—aligning with management’s high‑teens TriLink growth and large CleanCap/GMP orders—while Biologics Safety Testing (Cygnus) delivers steady, low‑single‑digit growth with strong margins. Protein Detection has effectively been de‑emphasized/exited. The mix shift supports the margin expansion and EBITDA guidance but keeps near‑term results exposed to lumpy, program‑timed GMP/CDMO orders until new GMP products scale in 2027.
MRVI Revenue by Segment
| Period | Nucleic Acid Production | Biologics Safety Testing | Protein Detection |
|---|---|---|---|
| Q3 2026Sep 30, 2026 | $28.35M | $17.50M | $0.00 |
| Q2 2026Jun 30, 2026 | $34.67M | $16.77M | $0.00 |
| Q1 2026Mar 31, 2026 | $47.48M | $18.36M | $0.00 |
| Q4 2025Dec 31, 2025 | $34.60M | $15.27M | $0.00 |
| Q3 2025Sep 30, 2025 | $25.35M | $16.28M | $0.00 |
| Q2 2025Jun 30, 2025 | $31.09M | $16.31M | $0.00 |
| Q1 2025Mar 31, 2025 | $28.75M | $18.10M | $0.00 |
| Q4 2024Dec 31, 2024 | $41.90M | $14.66M | $0.00 |
| Q3 2024Sep 30, 2024 | $53.84M | $15.18M | $0.00 |
| Q2 2024Jun 30, 2024 | $58.48M | $14.92M | $0.00 |
| Q1 2024Mar 31, 2024 | $46.02M | $18.16M | $0.00 |
| Q4 2023Dec 31, 2023 | $58.83M | $15.32M | $0.00 |
| Q3 2023Sep 30, 2023 | $51.23M | $15.64M | $0.00 |
| Q2 2023Jun 30, 2023 | $53.27M | $15.65M | $0.00 |
| Q1 2023Mar 31, 2023 | $61.45M | $17.57M | $0.00 |
| Q4 2022Dec 31, 2022 | $189.29M | $15.42M | $0.00 |
| Q3 2022Sep 30, 2022 | $174.88M | $16.38M | $0.00 |
| Q2 2022Jun 30, 2022 | $225.25M | $17.48M | $0.00 |
| Q1 2022Mar 31, 2022 | $223.65M | $20.64M | $0.00 |
| Q4 2021Dec 31, 2021 | $212.51M | $15.93M | $0.00 |
| Q3 2021Sep 30, 2021 | $182.90M | $16.63M | $5.28M |
| Q2 2021Jun 30, 2021 | $192.74M | $18.21M | $7.05M |
| Q1 2021Mar 31, 2021 | $124.17M | $17.65M | $6.63M |
| Q4 2020Dec 31, 2020 | $77.75M | $14.13M | $6.48M |
| Q3 2020Sep 30, 2020 | $67.66M | $14.11M | $6.09M |
| Q2 2020Jun 30, 2020 | $30.42M | $12.36M | $4.12M |
| Q1 2020Mar 31, 2020 | $30.49M | $14.29M | $6.20M |

